STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%

STRATA Skin Sciences, Inc.

2024-Q2 EPS reported -$0.99 revenue$15,189,000

Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.
Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.
Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).
XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.
Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.